Scalper1 News
Biogen Idec’s (BIIB) multiple-sclerosis drug Tecfidera moved a step closer to launch in the European Union Friday after Biogen won a long-fought battle for market exclusivity. Biogen stock jumped more than 10% in early trading in the stock market today, to an all-time high near 278. Tecfidera, which was launched in the U.S. earlier this year, got a positive panel vote in Europe in March, but Biogen then pushed back its launch date while it Scalper1 News
Scalper1 News